Core Viewpoint - The company, Giant Bio (02367.HK), has announced a share buyback plan, which has led to a 7.55% increase in its stock price, reaching HKD 39.34 [1] Group 1: Share Buyback Plan - The company plans to exercise the authority granted by shareholders at the annual general meeting on June 13, 2025, to repurchase shares [1] - The authorized buyback allows the company to repurchase up to approximately 103.6 million shares, which is 10% of the total issued shares (excluding treasury shares) as of the date of the resolution [1] - The company intends to use its own funds for the share buyback plan and expects that the implementation will not have a significant adverse impact on its working capital [1] Group 2: Authorization Expiry - The authorization for the share buyback will expire upon the earliest occurrence of the following: the conclusion of the next annual general meeting, the expiration of the period required by the articles of association or applicable laws for holding the next annual general meeting, or the revocation or amendment of the buyback authority by shareholders at a general meeting [1]
巨子生物(02367.HK)涨超7% 拟回购不超约1.036亿股